Baclofen formulations and methods of minimizing patient exposure to metabolite variations
US11491125B1 · kind B1 · utility
1Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2021 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Sep 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/197
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.